Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2024; 12(2): 346-353
Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.346
Use of MLC901 in cerebral venous sinus thrombosis: Three case reports
Anita Ante Arsovska, Narayanaswamy Venketasubramanian
Anita Ante Arsovska, Department of Urgent Neurology, University Clinic of Neurology, University Ss. Cyril and Methodius-Faculty of Medicine, Skopje 1000, North Macedonia
Narayanaswamy Venketasubramanian, Department of Neurology, Raffles Hospital, Singapore 188770, Singapore
Author contributions: Arsovska A contributed to the conceptualization, supervision, manuscript writing, editing, and data collection; Venketasubramanian N contributed to the conceptualization, manuscript writing, and editing; All authors have read and approved the final manuscript.
Informed consent statement: The Ethics Committee waived the requirement to obtain written informed consent from the patients for the anonymized reporting of their case details.
Conflict-of-interest statement: All the authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anita Ante Arsovska, MD, PhD, Professor, Department of Urgent Neurology, University Clinic of Neurology, University Ss. Cyril and Methodius-Faculty of Medicine, Bul. Majka Tereza 17, Skopje 1000, North Macedonia. anita70mk@yahoo.com
Received: August 17, 2023
Peer-review started: August 17, 2023
First decision: September 5, 2023
Revised: October 17, 2023
Accepted: December 27, 2023
Article in press: December 27, 2023
Published online: January 16, 2024
Processing time: 147 Days and 1.7 Hours
Abstract
BACKGROUND

Cerebral venous sinus thrombosis (CVT) is rare cause of cerebrovascular disease. The incidence is 0.5% of all stroke. The majority of affected patients are young adults (mean age: 35-40 years) with mild to moderate disabilities. Poor outcome with severe disability is seen in 13% of cases. Early diagnosis and treatment are important for good outcomes and preventing complications. Treatment options are limited and mostly based on consensus. NeuroAiD II™ (MLC901; Moleac Pte, Ltd, Singapore) has a potential beneficial role in post-stroke recovery, by aiding the natural brain recovery process.

CASE SUMMARY

MLC901 consists of nine natural herbal ingredients. Studies have shown its safety profile and aid in post stroke recovery. The aim of this case series was to demonstrate the potential role of MLC901 in stroke recovery of patients with cerebral venous sinus thrombosis (CVST) who received MLC901 in addition to standard of care. The prescribed dose of MLC901 is 400 mg/cap two capsules, three times a day. Data from these patients were prospectively collected at baseline and at monthly visits, for a duration of 3 mo. Outcome measures included adherence to therapy, side effects, National Institutes of Health Stroke Scale, Glasgow Coma Scale, modified Rankin Scale, and the Short Orientation-Memory-Concentration Test. MLC901 was well tolerated and no side effects were reported. All patients were stable with improved condition.

CONCLUSION

This case series highlights the potential therapeutic effects of MLC901 on CVST and provides support for further studies.

Keywords: MLC901; Cerebral venous sinus thrombosis; Anticoagulation therapy; Safety; Case report

Core Tip: The purpose of this study was to assess the potential role of NeuroAiD II™ (MLC901; Moleac Pte, Ltd, Singapore) in post-stroke recovery in a series of patients diagnosed with cerebral venous sinus thrombosis and treated with anticoagulation therapy.